Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22332359 | 0.87 | CYP3A4 (0.43) | TSHRKMT2AALDH1A1KDM4EGAA | |
| SCHEMBL18330407 | 0.87 | TSHR (0.51) | TSHRKMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL16591615 | 0.86 | HSD17B10 (0.41) | TSHRKMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL20381501 | 0.84 | HSD17B10 (0.45) | TSHRKMT2AALDH1A1MEN1CYP3A4 | |
| SCHEMBL16591617 | 0.82 | ITGB3 (0.49) | ALDH1A1KDM4ELMNAHSD17B10SIGMAR1 | |
| SCHEMBL18330505 | 0.79 | ALDH1A1 (0.50) | TSHRKMT2AALDH1A1HTTGAA | |
| SCHEMBL16591606 | 0.79 | DPP4 (0.43) | TSHRKMT2AALDH1A1LMNAMEN1 | |
| SCHEMBL16591602 | 0.78 | HSD17B10 (0.41) | TSHRKMT2AALDH1A1LMNAMEN1 | |
| SCHEMBL20939066 | 0.77 | HSD17B10 (0.46) | TSHRKMT2AALDH1A1LMNAGAA | |
| SCHEMBL20381522 | 0.76 | HSD17B10 (0.44) | TSHRKMT2AALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008334-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200255446-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255446-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | TSHR 4752/4885KMT2A 1832/4885ALDH1A1 2792/4885 |
| US-11008334-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | TSHR 4752/4885KMT2A 1832/4885ALDH1A1 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.